Comparison 6. Cycled inhaled tobramycin versus culture‐based inhaled tobramycin.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Participants with one or more isolates of P aeruginosa from respiratory tract	1		Odds Ratio (IV, Fixed, 95% CI)	Totals not selected
2 FEV₁ % predicted ‐ change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2.1 Mean duration of 70 weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Weight (kg) ‐ change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3.1 Mean duration of 70 weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Height (cm) ‐ change from baseline	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 Mean duration of 70 weeks	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Time to severe pulmonary exacerbation	1		Hazard Ratio (Fixed, 95% CI)	Totals not selected
6 Participants with one or more severe pulmonary exacerbations	1		Odds Ratio (IV, Fixed, 95% CI)	Totals not selected
7 Time to pulmonary exacerbation (any severity)	1		Hazard Ratio (Fixed, 95% CI)	Totals not selected
8 Participants with one or more pulmonary exacerbations (any severity)	1		Odds Ratio (IV, Fixed, 95% CI)	Totals not selected
9 Participants with new isolates of Stenotrophomonas maltophilia	1		Odds Ratio (IV, Fixed, 95% CI)	Totals not selected
10 Participants with one or more serious adverse event	1		Odds Ratio (IV, Fixed, 95% CI)	Totals not selected